Equities Analysts Offer Predictions for BCLI FY2024 Earnings

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) – Investment analysts at Zacks Small Cap decreased their FY2024 earnings per share (EPS) estimates for Brainstorm Cell Therapeutics in a research note issued to investors on Monday, January 6th. Zacks Small Cap analyst D. Bautz now forecasts that the biotechnology company will post earnings of ($3.01) per share for the year, down from their previous forecast of ($2.85). The consensus estimate for Brainstorm Cell Therapeutics’ current full-year earnings is ($2.85) per share. Zacks Small Cap also issued estimates for Brainstorm Cell Therapeutics’ Q4 2024 earnings at ($0.49) EPS, FY2025 earnings at ($1.60) EPS and FY2026 earnings at ($1.33) EPS.

Separately, StockNews.com downgraded Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday.

Brainstorm Cell Therapeutics Stock Performance

Shares of NASDAQ BCLI opened at $2.09 on Wednesday. The business’s 50 day moving average price is $1.74 and its 200-day moving average price is $3.32. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.89. The company has a market cap of $11.92 million, a price-to-earnings ratio of -0.44 and a beta of 0.29.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.